| Autor/in / Beteiligte Person: |
Chan, JD ; Scheffler, CM ; Munoz, I ; Sek, K ; Lee, JN ; Huang, YK ; Yap, KM ; Saw, NYL ; Li, J ; Chen, AXY ; Chan, CW ; Derrick, EB ; Todd, KL ; Tong, J ; Dunbar, PA ; Hoang, TX ; de Menezes MN ; Petley, EV ; Kim, JS ; Nguyen, D ; Leung, PSK ; So, J ; Deguit, C ; Zhu, J ; House, IG ; Kats, LM ; Scott, AM ; Solomon, BJ ; Harrison, SJ ; Oliaro, J ; Parish, IA ; Quinn, KM ; Neeson, PJ ; Slaney, CY ; Lai, J ; Beavis, PA ; Darcy, PK |
| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
- Language: English
- [Nature] 2024 May; Vol. 629 (8010), pp. 201-210. <i>Date of Electronic Publication: </i>2024 Apr 10.
- MeSH Terms: Forkhead Box Protein O1* / metabolism ; Forkhead Box Protein O1* / genetics ; Immunotherapy, Adoptive* ; Receptors, Chimeric Antigen* / immunology ; Receptors, Chimeric Antigen* / metabolism ; T-Lymphocytes* / immunology ; T-Lymphocytes* / metabolism ; T-Lymphocytes* / cytology ; Stem Cells* / cytology ; Stem Cells* / immunology ; Stem Cells* / metabolism ; Neoplasms* / immunology ; Neoplasms* / pathology ; Neoplasms* / therapy ; Humans ; Mice ; Cell Line, Tumor ; Mitochondria / metabolism ; Phenotype ; Tumor Microenvironment / immunology
- References: Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014). (PMID: 25317870426753110.1056/NEJMoa1407222) ; Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011). (PMID: 21832238339309610.1126/scitranslmed.3002842) ; Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002–1014 (2023). (PMID: 3676285110.1056/NEJMoa2213614) ; San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335–347 (2023). (PMID: 3727251210.1056/NEJMoa2303379) ; Mardiana, S., Solomon, B. J., Darcy, P. K. & Beavis, P. A. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci. Transl. Med. 11, eaaw2293 (2019). (PMID: 3116792510.1126/scitranslmed.aaw2293) ; Chan, J. D. et al. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat. Rev. Immunol. 21, 769–784 (2021). (PMID: 3387987310.1038/s41577-021-00539-6) ; van Bruggen, J. A. C. et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 + T cells and impede CAR T-cell efficacy. Blood 134, 44–58 (2019). (PMID: 31076448702237510.1182/blood.2018885863) ; Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018). (PMID: 29713085611761310.1038/s41591-018-0010-1) ; Blank, C. U. et al. Defining T cell exhaustion. Nat. Rev. Immunol. 19, 665–674 (2019). (PMID: 31570879728644110.1038/s41577-019-0221-9) ; Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017). (PMID: 2821336610.1158/1078-0432.CCR-16-2848) ; Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2019). (PMID: 10.1016/j.cell.2018.10.038) ; Giuffrida, L. et al. IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol. Ther. 28, 2379–2393 (2020). (PMID: 32735774764766710.1016/j.ymthe.2020.07.018) ; Klebanoff, C. A. et al. Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102, 9571–9576 (2005). (PMID: 15980149117226410.1073/pnas.0503726102) ; Siddiqui, I. et al. Intratumoral Tcf1 + PD-1 + CD8 + T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e110 (2019). (PMID: 3063523710.1016/j.immuni.2018.12.021) ; Guo, Y. et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24, 1277–1286 (2018). (PMID: 2913834010.1158/1078-0432.CCR-17-0432) ; Soriano-Baguet, L. & Brenner, D. Metabolism and epigenetics at the heart of T cell function. Trends Immunol. 44, 231–244 (2023). (PMID: 3677433010.1016/j.it.2023.01.002) ; Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021). (PMID: 33795428804910310.1126/science.aba1786) ; Hirabayashi, K. et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904–918 (2021). (PMID: 34746799857056910.1038/s43018-021-00244-2) ; Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788–E7797 (2016). (PMID: 27849617513775810.1073/pnas.1610544113) ; Kagoya, Y. et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest. 126, 3479–3494 (2016). (PMID: 27548527500494610.1172/JCI86437) ; Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983–995 (2021). (PMID: 34282330831910910.1038/s41590-021-00964-8) ; Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293–300 (2019). (PMID: 31802004694432910.1038/s41586-019-1805-z) ; Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759–772 (2019). (PMID: 30890531668756110.1158/2326-6066.CIR-18-0466) ; Tejera, M. M., Kim, E. H., Sullivan, J. A., Plisch, E. H. & Suresh, M. FoxO1 controls effector-to-memory transition and maintenance of functional CD8 T cell memory. J. Immunol. 191, 187–199 (2013). (PMID: 2373388210.4049/jimmunol.1300331) ; Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10, 176–184 (2009). (PMID: 19136962285647110.1038/ni.1689) ; Chen, Z. et al. In vivo CD8 + T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262–1280.e1222 (2021). (PMID: 33636129805435110.1016/j.cell.2021.02.019) ; Yang, C. Y. et al. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8 + T cell subsets. Nat. Immunol. 12, 1221–1229 (2011). (PMID: 2205728910.1038/ni.2158) ; Utzschneider, D. T. et al. Active maintenance of T cell memory in acute and chronic viral infection depends on continuous expression of FOXO1. Cell Rep. 22, 3454–3467 (2018). (PMID: 29590615594218410.1016/j.celrep.2018.03.020) ; Klotz, L. O. et al. Redox regulation of FoxO transcription factors. Redox Biol. 6, 51–72 (2015). (PMID: 26184557451162310.1016/j.redox.2015.06.019) ; Beavis, P. A. et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Invest. 127, 929–941 (2017). (PMID: 28165340533071810.1172/JCI89455) ; Dong, E. et al. IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells. Signal Transduct. Target. Ther. 6, 20 (2021). (PMID: 33454722781152910.1038/s41392-020-00357-7) ; Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697–5706 (2011). (PMID: 2174277210.1158/0008-5472.CAN-11-0103) ; Larson, R. C. et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature 604, 563–570 (2022). (PMID: 3541868710.1038/s41586-022-04585-5) ; Mardiana, S. et al. A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells. Cancer Res. 77, 1296–1309 (2017). (PMID: 2808240110.1158/0008-5472.CAN-16-1831) ; Kantari-Mimoun, C. et al. CAR T-cell entry into tumor islets is a two-step process dependent on IFNγ and ICAM-1. Cancer Immunol. Res. 9, 1425–1438 (2021). (PMID: 3468648910.1158/2326-6066.CIR-20-0837) ; Monteiro, L. B., Davanzo, G. G., de Aguiar, C. F. & Moraes-Vieira, P. M. M. Using flow cytometry for mitochondrial assays. MethodsX 7, 100938 (2020). (PMID: 32551241728976010.1016/j.mex.2020.100938) ; Jang, K. J. et al. Mitochondrial function provides instructive signals for activation-induced B-cell fates. Nat. Commun. 6, 6750 (2015). (PMID: 2585752310.1038/ncomms7750) ; Rad, S. M. A., Poudel, A., Tan, G. M. Y. & McLellan, A. D. Promoter choice: Who should drive the CAR in T cells? PLoS ONE 15, e0232915 (2020). (PMID: 10.1371/journal.pone.0232915) ; Wherry, E. J. et al. Molecular signature of CD8 + T cell exhaustion during chronic viral infection. Immunity 27, 670–684 (2007). (PMID: 1795000310.1016/j.immuni.2007.09.006) ; Shan, Q. et al. Tcf1–CTCF cooperativity shapes genomic architecture to promote CD8 + T cell homeostasis. Nat. Immunol. 23, 1222–1235 (2022). (PMID: 35882936957996410.1038/s41590-022-01263-6) ; Delpoux, A. et al. FOXO1 constrains activation and regulates senescence in CD8 T cells. Cell Rep. 34, 108674 (2021). (PMID: 3350341310.1016/j.celrep.2020.108674) ; Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4 + CAR T cells. Nature 602, 503–509 (2022). (PMID: 35110735916691610.1038/s41586-021-04390-6) ; Klebanoff, C. A. et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight 2, e95103 (2017). (PMID: 29212954575230410.1172/jci.insight.95103) ; Kousteni, S. FoxO1, the transcriptional chief of staff of energy metabolism. Bone 50, 437–443 (2012). (PMID: 2181624410.1016/j.bone.2011.06.034) ; Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8 + T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell 185, 4049–4066.e4025 (2022). (PMID: 3620862310.1016/j.cell.2022.09.020) ; Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446–453 (2020). (PMID: 3189666010.1126/science.aay5967) ; Piechocki, M. P., Ho, Y. S., Pilon, S. & Wei, W. Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171, 5787–5794 (2003). (PMID: 1463408710.4049/jimmunol.171.11.5787) ; Darcy, P. K. et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J. Immunol. 164, 3705–3712 (2000). (PMID: 1072572910.4049/jimmunol.164.7.3705) ; DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530–1532 (2012). (PMID: 22539670335684710.1093/bioinformatics/bts196) ; Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018). (PMID: 2915595010.1093/nar/gkx1098) ; Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010). (PMID: 1991030810.1093/bioinformatics/btp616) ; McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288–4297 (2012). (PMID: 22287627337888210.1093/nar/gks042) ; Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. Preprint at bioRxiv https://doi.org/10.1101/060012 (2019). ; Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005). (PMID: 16199517123989610.1073/pnas.0506580102) ; Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011). (PMID: 21546393310619810.1093/bioinformatics/btr260) ; Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015). (PMID: 26771021470796910.1016/j.cels.2015.12.004) ; Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27–30 (2000). (PMID: 1059217310240910.1093/nar/28.1.27) ; Pont, F., Tosolini, M. & Fournie, J. J. Single-cell signature explorer for comprehensive visualization of single cell signatures across scRNA-seq datasets. Nucleic Acids Res. 47, e133 (2019). (PMID: 31294801686834610.1093/nar/gkz601) ; Gaspar, J. M. NGmerge: merging paired-end reads via novel empirically-derived models of sequencing errors. BMC Bioinformatics 19, 536 (2018). (PMID: 30572828630240510.1186/s12859-018-2579-2) ; Pohl, A. & Beato, M. bwtool: a tool for bigWig files. Bioinformatics 30, 1618–1619 (2014). (PMID: 24489365402903110.1093/bioinformatics/btu056) ; Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data. Nat. Methods 14, 975–978 (2017). (PMID: 28825706562314610.1038/nmeth.4401) ; Castro-Mondragon, J. A. et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 50, D165–D173 (2022). (PMID: 3485090710.1093/nar/gkab1113)
- Substance Nomenclature: 0 (Forkhead Box Protein O1) ; 0 (FOXO1 protein, human) ; 0 (Receptors, Chimeric Antigen)
- Entry Date(s): Date Created: 20240410 Date Completed: 20240501 Latest Revision: 20240509
- Update Code: 20240510
- PubMed Central ID: PMC11062918
|
